Bortezomib mediated BRCAness in Myeloma cells: novel therapeutic approach combining PARP1-2 and 26S proteasome inhibitors.

硼替佐米介导骨髓瘤细胞中的 BRCA：结合 PARP1-2 和 26S 蛋白酶体抑制剂的新型治疗方法。

• 批准号: 267173
• 负责人: Bahlis Nizar J
• 金额: $ 38.09万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-09-01 至 2016-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=267173&lang=en
• 关键词: Multiple Myeloma; Parp And Dna Repair; Phase I Clinical Trial; Proteasome Inhibitors

Multiple myeloma is the second most common form of blood cancers and it remains incurable despite the addition of novel therapeutic strategies for this disease. Cancer cells invariably escape the therapeutic effect of drugs by rearranging their genetic ma

多发性骨髓瘤是第二种最常见的血癌，尽管有新的治疗策略，它仍然是无法治愈的。癌细胞总是通过重新排列它们的基因来逃避药物的治疗效果